Evotec SE Stock (NASDAQ:EVO)
Previous Close
$3.41
52W Range
$2.85 - $12.40
50D Avg
$4.04
200D Avg
$6.50
Market Cap
$1.26B
Avg Vol (3M)
$90.75K
Beta
1.05
Div Yield
-
EVO Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. |
| RDY | Dr. Reddy's Laboratories Limited |
| ANIP | ANI Pharmaceuticals, Inc. |
| PAHC | Phibro Animal Health Corporation |
| NBIX | Neurocrine Biosciences, Inc. |
| RGC | Regencell Bioscience Holdings Limited |
| SSIC | Silver Spike Investment Corp. |
| DCPH | Deciphera Pharmaceuticals, Inc. |
| PBH | Prestige Consumer Healthcare Inc. |
| PCRX | Pacira BioSciences, Inc. |
| COLL | Collegium Pharmaceutical, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |